imatinib mesylate has been researched along with Histiocytic Sarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blum, S; Cairoli, A; de Leval, L; Homicsko, K; Michielin, O; Missiaglia, E; Naveiras, O; Voruz, S | 1 |
| Bisig, B; Blum, S; Cairoli, A; de Leval, L; Homicsko, K; Martins, F; Michielin, O; Missiaglia, E; Naveiras, O; Voruz, S | 1 |
2 other study(ies) available for imatinib mesylate and Histiocytic Sarcoma
| Article | Year |
|---|---|
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Combined Modality Therapy; Histiocytic Sarcoma; Humans; Imatinib Mesylate; Immunohistochemistry; Immunophenotyping; Male; Molecular Targeted Therapy; Positron Emission Tomography Computed Tomography; Pyridones; Pyrimidinones; Retreatment; Symptom Assessment; Treatment Outcome | 2018 |
Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
Topics: Histiocytic Sarcoma; Humans; Imatinib Mesylate; Protein-Tyrosine Kinases; Pyridones; Pyrimidinones | 2018 |